Hydroxymethylnitrofurazone (NFOH) decreases parasitaemia, parasitism and tissue lesion caused by infection with the Bolivia Trypanosoma cruzi type I strain in Swiss and C57BL/6 mice

dc.contributor.authorScarim, Cauê Benito [UNESP]
dc.contributor.authorde Andrade, Cleverton Roberto [UNESP]
dc.contributor.authorFalcone, Rossana [UNESP]
dc.contributor.authorAmbrozini, Letícia Moreno [UNESP]
dc.contributor.authorSenhorelli, Vitor Izidoro [UNESP]
dc.contributor.authorda Rosa, João Aristeu [UNESP]
dc.contributor.authorChin, Chung Man [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.date.accessioned2023-07-29T16:02:34Z
dc.date.available2023-07-29T16:02:34Z
dc.date.issued2022-01-01
dc.description.abstractThe chemical hydroxymethylation of the antimicrobial nitrofurazone leads to the prodrug NFOH, also increases the anti-T. cruzi activities (in vitro and in vivo), as well as showed non-genotoxic (Ames and micronucleus assays). In the present study, we assessed the anti-T. cruzi effect of the NFOH In vivo-in acute Swiss and C57Bl/6 experimental Chagas models. The treatment started at 5 days post-infection during 20 consecutive days (orally, once day, 150mg/kg), and the parasitaemia as well as histopathology analysis were performed. In both experimental murine models, NFOH was able to reduce parasitemia blood avoiding parasitic reactivation, during immunosuppression period (dexamethasone 5mg/kg, 14 days), in 100% of the mice, and decrease tissue parasite nests, demonstrating absence of amastigote forms in all organs (100%) analyzed, data similar to benznidazole (BZN). Therefore, the results shown here pointing to the NFOH as promising compound for further preclinical studies, being a high potential drug to effective and safe chemotherapy to Chagas disease.en
dc.description.affiliationSao Paulo State University “Júlio de Mesquita Filho” UNESP Faculty of Pharmaceutical Sciences Department of Pharmaceuticals and Medicines, SP
dc.description.affiliationUnespSao Paulo State University “Júlio de Mesquita Filho” UNESP Faculty of Pharmaceutical Sciences Department of Pharmaceuticals and Medicines, SP
dc.identifierhttp://dx.doi.org/10.1590/s2175-97902022e20277
dc.identifier.citationBrazilian Journal of Pharmaceutical Sciences, v. 58.
dc.identifier.doi10.1590/s2175-97902022e20277
dc.identifier.issn2175-9790
dc.identifier.issn1984-8250
dc.identifier.scopus2-s2.0-85145907565
dc.identifier.urihttp://hdl.handle.net/11449/249542
dc.language.isoeng
dc.relation.ispartofBrazilian Journal of Pharmaceutical Sciences
dc.sourceScopus
dc.subjectAcute stage
dc.subjectBenznidazole (BZN)
dc.subjectBolivia strain
dc.subjectChagas disease
dc.subjectHydroxymethylnitrofurazone (NFOH)
dc.subjectTrypanosoma cruzi
dc.titleHydroxymethylnitrofurazone (NFOH) decreases parasitaemia, parasitism and tissue lesion caused by infection with the Bolivia Trypanosoma cruzi type I strain in Swiss and C57BL/6 miceen
dc.typeArtigo
unesp.author.orcid0000-0002-2540-6395[1]

Arquivos